Modality
mAb
MOA
HER2
Target
AuroraA
Pathway
Lipid Met
Melanoma
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
Aug 2019
→ Apr 2031
Phase 1Current
NCT06968427
1,073 pts·Melanoma
2019-08→TBD·Terminated
NCT04206014
2,179 pts·Melanoma
2021-03→2031-04·Completed
3,252 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-162w awayOrphan Drug· Melanoma
2031-04-045.0y awayPh2 Data· Melanoma
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Termina…
P1/2
Complet…
Catalysts
Orphan Drug
2026-04-16 · 2w away
Melanoma
Ph2 Data
2031-04-04 · 5.0y away
Melanoma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06968427 | Phase 1/2 | Melanoma | Terminated | 1073 | EDSS |
| NCT04206014 | Phase 1/2 | Melanoma | Completed | 2179 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |